Fig. 1 · Structure
Documents & Downloads
Cymarin
Cardiac Glycoside
Cymarin, a cardiac glycoside, primarily inhibits Palytoxin (PTX)-induced potassium release with an IC50 of 0.42 μM. This compound demonstrates notable antitumor activity against breast and pancreatic cancer, making it a valuable tool in cancer research. Additionally, Cymarin exhibits antifeedant properties and growth inhibitory effects, providing potential applications as a crop protectant in agricultural studies.
In Stock
Free Aliquoting for Your Order
Tell us your preferred amount per vial. We’ll confirm the options.
Specifications
| Manufacturer | Adooq Bioscience |
|---|---|
| CAS Number | 508-77-0 |
| Applications | Cardiac Glycoside |
| Formula | C30H44O9 |
| Molecular Weight | 548.66 |
| SMILES | O=C[C@@]12[C@]3([H])[C@](CC[C@@]1(C[C@@H](O[C@@]4([H])C[C@@H]([C@H](O)[C@@H](C)O4)OC)CC2)O)([H])[C@@]5([C@@](C)([C@@H](C(CO6)=CC6=O)CC5)CC3)O |
Storage & Solubility
In Vitro Solubility
Reported Solubility
No reported solubility data are available for this product.
Preparing Stock Solutions
| Concentration | |
|---|---|
Values use four significant digits. Prepare to the final solution volume; this is not the volume of solvent to add.
Stock preparation is unavailable for this product molecular weight.
Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.
Storage
Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.